Showing results (61-70 of 96) with videos related to
Sort By:
Pageof 10
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 12, 2002
TACE mRNA expression in peripheral mononudear cells precedes new lesions on MRI in multiple sclerosisT Seifert, B C Kieseier, S Ropele, et al.Critical Care Medicine|August 16, 2001
Endothelin-1 blockade corrects mesenteric hypoperfusion in a porcine low cardiac output modelD Burgener, M Laesser, M Treggiari-Venzi, et al.Scientific Reports|January 26, 2019
Attenuation of murine sclerodermatous models by the selective S1P1 receptor modulator cenerimodMiyu Kano, Tadahiro Kobayashi, Mutsumi Date, et al.Clinical Pharmacokinetics|December 23, 2015
Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose SelectionAndreas Krause, Jochen Zisowsky, Daniel S Strasser, et al.Journal of Proteome Research|September 2, 2020
Immunoaffinity Targeted Mass Spectrometry Analysis of Human Plasma Samples Reveals an Imbalance of Active and Inactive CXCL10 in Primary Sjögren's Syndrome Disease PatientsAlexander Schmidt, Hervé Farine, Marcel P Keller, et al.AJNR. American Journal of Neuroradiology|March 24, 2000
Diffusion-weighted MR imaging of the spinal cordR Bammer, F Fazekas, M Augustin, et al.South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|April 6, 2001
Evaluating the clinical management of severely malnourished children--a study of two rural district hospitalsT Puoane, D Sanders, M Chopra, et al.Muscle & Nerve|August 3, 2000
Clinical predominance of proximal upper limb weakness in CMT1A syndromeM Auer-Grumbach, K Wagner, S Strasser-Fuchs, et al.Journal of Clinical Pharmacology|February 7, 2015
A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjectsMartine Géhin, Daniel S Strasser, Jochen Zisowsky, et al.British Journal of Clinical Pharmacology|September 27, 2023
Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adultsMarie-Laure Boof, Martine Géhin, Christine Voors-Pette, et al.Pageof 10